CAR-T companies are on the rise, supported by growing investment flowing into the sector and landmark approvals of CAR-T cell therapies, including Kymriah, Yescarta, Tecartus and Breyanzi.
There have also been major acquisitions within the CAR-T space, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as did Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.
To track the competitors who compose this rapidly expanding market, BioInformant has released a global database of all known CAR-T cell therapy companies.
We originally developed it for our own purposes, but more and more of our readers have been begging for access.
Features of the CAR-T Company Database
Chimeric antigen receptors (CAR) T cells are genetically engineered allogeneic cells that are developed in the laboratory and infused into a patient, to help in detecting and fighting cancer.
The database features the following information for all known CAR-T market competitors:
- Company Name
- CAR-T Technology
- Disease Targets
- Description of CAR-T Involvement
- City / State
- Link to CAR-T Programs
- Company Website
Use this list of CAR-T companies to:
- Identify global competitors within the CAR-T marketplace
- Quantify CAR-T products in late-stage development
- Reveal preclinical and clinical programs supporting CAR-T development
- Spot regions that are “hotspots” for CAR-T companies
- Identify potential partners and collaborators
Database of CAR-T Cell Therapy Companies
It takes our team of analysts hours of exhaustive research to uncover these CAR-T cell therapy companies from across the globe and requires the translation of sites and clinical trial programs across dozens of languages.
Thankfully, we have a talented, multilingual team who is up to the task of organizing all known CAR-T cell therapy companies worldwide (129 total).
Because we continuously update this database to reflect new competitors entering the CAR-T cell therapy marketplace, we are confident that you will find it to be invaluable resource.
With the value of CAR-T IPO’s nearing $2 billion, CAR-T financing rounds approaching $4 billion, and nearly $100 billion of market capitalization from CAR-T companies in recent years, this is clearly a hot market segment.
Would you benefit from knowing the identities of all known CAR-T market competitors worldwide?